A new era of neoadjuvant treatment with Pertuzumab: Should the 10-lymph node guideline for axillary lymph node dissection in breast cancer be revised?

Autor: O'Leary MP; Department of Surgery, Division of Surgical Oncology, Harbor UCLA Medical Center, Torrance, CA, USA., Beckord BJ; Department of Surgery, Division of Surgical Oncology, Harbor UCLA Medical Center, Torrance, CA, USA., Mock KE; Department of Surgery, Division of Surgical Oncology, Harbor UCLA Medical Center, Torrance, CA, USA., Venegas RJ; Department of Pathology, Division of Cytopathology, Harbor UCLA Medical Center, Torrance, CA, USA., Yeh JJ; Department of Medicine, Division of Medical Oncology, Harbor UCLA Medical Center, Torrance, CA, USA., Dauphine CE; Department of Surgery, Division of Surgical Oncology, Harbor UCLA Medical Center, Torrance, CA, USA., Ozao-Choy JJ; Department of Surgery, Division of Surgical Oncology, Harbor UCLA Medical Center, Torrance, CA, USA.

Publikováno v: Cancer reports (Hoboken, N.J.) [Cancer Rep (Hoboken)] 2018 Dec; Vol. 1 (4), pp. e1132. Date of Electronic Publication: 2018 Sep 16.